SCHEMBL19976944

SCHEMBL19976944

COC[C@H](C)N/C(=N/C(=O)c1ccc(F)c(F)c1)Nc1[nH]nc2cc(C(F)(F)F)ccc12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 4/20 0.36
TRPA1 O75762 3/20 0.33
PDE2A O00408 1/20 0.33
HTT P42858 3/20 0.33
KDM4E B2RXH2 2/20 0.33
POLB P06746 1/20 0.33
KMT2A Q03164 1/20 0.33
ALDH1A1 P00352 3/20 0.33
HPGD P15428 3/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
GSK3B P49841 1/20 0.33
LMNA P02545 1/20 0.32
TP53 P04637 1/20 0.32
MAPT P10636 1/20 0.32
MAP2K4 P45985 1/20 0.32
MAPK6 Q16659 1/20 0.32
MAPKAPK5 Q8IW41 1/20 0.32
RAB9A P51151 1/20 0.32
NAMPT P43490 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19976851 0.94 POLB (0.35) MAPK1TRPA1PDE2AHTTKDM4E
SCHEMBL19976798 0.93 PTGES (0.36) MAPK1KDM4EPOLBKMT2AALDH1A1
SCHEMBL19976928 0.91 CTNNB1 (0.37) MAPK1HTTKDM4EPOLBKMT2A
SCHEMBL19976727 0.91 GSK3B (0.36) MAPK1TRPA1PDE2AHTTKMT2A
SCHEMBL19976784 0.90 MAPK1 (0.38) MAPK1POLBMAP2K4NAMPT
SCHEMBL19976777 0.88 POLB (0.39) MAPK1POLBKMT2AHPGDLMNA
SCHEMBL16752809 0.85 GSK3B (0.48) MAPK1TRPA1GSK3BMAP2K4MAPK6
SCHEMBL16752808 0.85 GSK3B (0.48) MAPK1TRPA1GSK3BMAP2K4MAPK6
SCHEMBL16752811 0.85 GSK3B (0.48) MAPK1TRPA1GSK3BMAP2K4MAPK6
SCHEMBL19976737 0.84 HPGD (0.35) MAPK1HTTKDM4EPOLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9920012-B2 Indazole guanidine F1F0-ATPase inhibitors and therapeutic uses thereof LYCERA CORPORATION (US) 2018-03-20 US disclosed